Novartis AG - Product Pipeline Review - 2016

  • ID: 3674257
  • Company Profile
  • 489 pages
  • Global Markets Direct
  • Novartis AG
1 of 4
Novartis AG - Product Pipeline Review - 2016

Summary

‘Novartis AG - Product Pipeline Review - 2016’, provides an overview of the Novartis AG’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Novartis AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Novartis AG
- The report provides overview of Novartis AG including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Novartis AG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Novartis AG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Novartis AG’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Novartis AG
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Novartis AG’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Novartis AG Snapshot

Novartis AG Overview

Key Information

Key Facts

Novartis AG - Research and Development Overview

Key Therapeutic Areas

Novartis AG - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Pipeline Products - Out-Licensed Products

Novartis AG - Pipeline Products Glance

Novartis AG - Late Stage Pipeline Products

Novartis AG - Clinical Stage Pipeline Products

Novartis AG - Early Stage Pipeline Products

Novartis AG - Drug Profiles

ceritinib

dabrafenib mesylate + trametinib dimethyl sulfoxide

eltrombopag olamine

everolimus

serelaxin

trametinib dimethyl sulfoxide

zoledronic acid

imatinib mesylate

panobinostat

pazopanib hydrochloride

(glycopyrrolate + indacaterol maleate + mometasone fuorate)

(indacaterol maleate + mometasone furoate)

(sacubitril + valsartan)

alpelisib

bimagrumab

buparlisib hydrochloride

canakinumab

dabrafenib mesylate

fevipiprant

fingolimod hydrochloride

midostaurin

nilotinib

ofatumumab

osilodrostat phosphate

oxytocin

pasireotide

pasireotide ER

ranibizumab

ribociclib

secukinumab

siponimod

CDZ-173

clofazimine

CNP-520

(dectrekumab + VAK-694)

afuresertib hydrochloride

aldesleukin

BHQ-880

BVS-857

capmatinib

CFZ-533

cipargamin

CJM-112

dectrekumab

EGF-816

elgemtumab

EMA-401

FCR-001

GSK-2285921

HSC-835

iloperidone

infigratinib

KAF-156

KRP-203

LCL-161

LFX-453

LHW-090

ligelizumab

LJN-452

LMI-070

mavoglurant

MCS-110

octreotide acetate long acting

pradigastat sodium

ruxolitinib phosphate

selurampanel

sonidegib phosphate

tesidolumab

tisagenlecleucel-T

trametinib dimethyl sulfoxide + uprosertib

uprosertib

VAY-736

BZF-961

CGF-166

CSJ-137

CSJ-148

FGF-401

HDM-201

LAG-525

lapatinib ditosylate

MGB-453

PDR-001

PIM-447

RAF-265

sotrastaurin acetate

ABL-001

AV-380

Cellular Immunotherapy to Target c-Met for Oncology

Cellular Immunotherapy to Target CD22 for Acute Lymphoblastic Leukemia

Cellular Immunotherapy to Target EGFR for Glioblastoma

CGM-097

CLR-325

huCART19

IDH-305

IMP-701

LEQ-506

LGK-974

LML-134

LNA-043

LXH-254

LXS-196

MesoCART

NOV-10

NOV-11

NOV-7

NOV-8

NOV-9

octreotide acetate LAR

PBF-509

PCA-062

QCC-374

CART-123

Cellular Immunotherapy to Target B-Cell Maturation Factor for Multiple Myeloma

Antibody to Inhibit PD-L1 for Oncology

AUSRM-057

BLZ-945

BQS-481

BVB-808

Cellular Immunotherapy Program for Oncology

Cellular Immunotherapy to Target GD2 for Neuroblastoma

CHZ-868

cosyntropin ER

ESK-1

GNFPf-5069

Kartogenin

KR-22809

LCZ-960

LGB-321

LKZ-145

LQN-725

Monoclonal Antibody to Inhibit CXCR2 for Respiratory Diseases

NIBR-0213

NITD-349

NITD-916

NVPQBE-170

NVPTNKS-656

OXB-302

RP-6503

Small Molecule to Agonize GPR119 for Type 2 Diabetes

Small Molecule to Agonize GPR39 for Type 2 Diabetes

Small Molecule to Agonize Nurr1 for Multiple Sclerosis

Small Molecule to Inhibit LRRK2 for Parkinson's Disease

Small Molecule to Inhibit OX2R for Insomnia

Small Molecules to Antagonize VEGFR2 for Solid Tumors

Small Molecules to Inhibit Cytochrome bc1 Complex for Tuberculosis

Small Molecules to Inhibit Dipeptidyl Peptidase IV for Type 2 Diabetes

Small Molecules to Inhibit Pan PI3K for Ovarian Cancer

Small Molecules to Inhibit Pan-RAF Kinase for Oncology

Small Molecules to Inhibit Renin for Hypertension

XOMA-089

ESBA-903 SR

LJH-685

Monoclonal Antibodies to Inhibit CTLA4 and PD-1 for Oncology

Small Molecule to Agonize Adrenergic Beta-2 Receptor for COPD

Small Molecules for Tuberculosis

Small Molecules for Undisclosed Indication

Small Molecules to Antagonize NR2B for Depression

Small Molecules to Inhibit Acetyl-CoA Carboxylase for Metabolic, Cardiovascular and Infections

Small Molecules to Inhibit CFTR for Secretory Diarrhea

Small Molecules to Inhibit FPPS for Soft Tissue Cancer

Small Molecules to Inhibit PfATP4 for Malaria

Small Molecules to Inhibit PI4KIIIbeta for HCV

Novartis AG - Pipeline Analysis

Novartis AG - Pipeline Products by Target

Novartis AG - Pipeline Products by Route of Administration

Novartis AG - Pipeline Products by Molecule Type

Novartis AG - Pipeline Products by Mechanism of Action

Novartis AG - Recent Pipeline Updates

Novartis AG - Dormant Projects

Novartis AG - Discontinued Pipeline Products

Novartis AG - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

Novartis AG - Company Statement

Novartis AG - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Novartis AG, Key Information

Novartis AG, Key Facts

Novartis AG - Pipeline by Indication, 2016

Novartis AG - Pipeline by Stage of Development, 2016

Novartis AG - Monotherapy Products in Pipeline, 2016

Novartis AG - Combination Treatment Modalities in Pipeline, 2016

Novartis AG - Partnered Products in Pipeline, 2016

Novartis AG - Partnered Products/ Combination Treatment Modalities, 2016

Novartis AG - Out-Licensed Products in Pipeline, 2016

Novartis AG - Out-Licensed Products/ Combination Treatment Modalities, 2016

Novartis AG - Pre-Registration, 2016

Novartis AG - Filing rejected/Withdrawn, 2016

Novartis AG - Phase III, 2016

Novartis AG - Phase II, 2016

Novartis AG - Phase I, 2016

Novartis AG - Phase 0, 2016

Novartis AG - Preclinical, 2016

Novartis AG - Discovery, 2016

Novartis AG - Pipeline by Target, 2016

Novartis AG - Pipeline by Route of Administration, 2016

Novartis AG - Pipeline by Molecule Type, 2016

Novartis AG - Pipeline Products by Mechanism of Action, 2016

Novartis AG - Recent Pipeline Updates, 2016

Novartis AG - Dormant Developmental Projects,2016

Novartis AG - Discontinued Pipeline Products, 2016

Novartis AG, Subsidiaries

List of Figures

Novartis AG - Pipeline by Top 10 Indication, 2016

Novartis AG - Pipeline by Stage of Development, 2016

Novartis AG - Monotherapy Products in Pipeline, 2016

Novartis AG - Combination Treatment Modalities in Pipeline, 2016

Novartis AG - Partnered Products in Pipeline, 2016

Novartis AG - Out-Licensed Products in Pipeline, 2016

Novartis AG - Pipeline by Top 10 Target, 2016

Novartis AG - Pipeline by Top 10 Route of Administration, 2016

Novartis AG - Pipeline by Top 10 Molecule Type, 2016

Novartis AG - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll